• Richard M Martin, Jenny L Donovan, Emma L Turner, Chris Metcalfe, Grace J Young, Eleanor I Walsh, J Athene Lane, Sian Noble, Steven E Oliver, Simon Evans, SterneJonathan A CJACDepartment of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and, Peter Holding, Yoav Ben-Shlomo, Peter Brindle, Naomi J Williams, Elizabeth M Hill, Siaw Yein Ng, Jessica Toole, Marta K Tazewell, Laura J Hughes, Charlotte F Davies, Joanna C Thorn, Elizabeth Down, Davey SmithGeorgeGDepartment of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England., David E Neal, Freddie C Hamdy, and CAP Trial Group.
• Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
• JAMA. 2018 Mar 6; 319 (9): 883895883-895.

ImportanceProstate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.ObjectiveTo evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality.Design, Setting, And ParticipantsThe Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) included 419 582 men aged 50 to 69 years and was conducted at 573 primary care practices across the United Kingdom. Randomization and recruitment of the practices occurred between 2001 and 2009; patient follow-up ended on March 31, 2016.InterventionAn invitation to attend a PSA testing clinic and receive a single PSA test vs standard (unscreened) practice.Main Outcomes And MeasuresPrimary outcome: prostate cancer-specific mortality at a median follow-up of 10 years. Prespecified secondary outcomes: diagnostic cancer stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostate cancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSA screening clinic.ResultsAmong 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included in the analysis (n = 408 825; 98%). In the intervention group, 75 707 (40%) attended the PSA testing clinic and 67 313 (36%) underwent PSA testing. Of 64 436 with a valid PSA test result, 6857 (11%) had a PSA level between 3 ng/mL and 19.9 ng/mL, of whom 5850 (85%) had a prostate biopsy. After a median follow-up of 10 years, 549 (0.30 per 1000 person-years) died of prostate cancer in the intervention group vs 647 (0.31 per 1000 person-years) in the control group (rate difference, -0.013 per 1000 person-years [95% CI, -0.047 to 0.022]; rate ratio [RR], 0.96 [95% CI, 0.85 to 1.08]; P = .50). The number diagnosed with prostate cancer was higher in the intervention group (n = 8054; 4.3%) than in the control group (n = 7853; 3.6%) (RR, 1.19 [95% CI, 1.14 to 1.25]; P < .001). More prostate cancer tumors with a Gleason grade of 6 or lower were identified in the intervention group (n = 3263/189 386 [1.7%]) than in the control group (n = 2440/219 439 [1.1%]) (difference per 1000 men, 6.11 [95% CI, 5.38 to 6.84]; P < .001). In the analysis of all-cause mortality, there were 25 459 deaths in the intervention group vs 28 306 deaths in the control group (RR, 0.99 [95% CI, 0.94 to 1.03]; P = .49). In the instrumental variable analysis for prostate cancer mortality, the adherence-adjusted causal RR was 0.93 (95% CI, 0.67 to 1.29; P = .66).Conclusions And RelevanceAmong practices randomized to a single PSA screening intervention vs standard practice without screening, there was no significant difference in prostate cancer mortality after a median follow-up of 10 years but the detection of low-risk prostate cancer cases increased. Although longer-term follow-up is under way, the findings do not support single PSA testing for population-based screening.Trial RegistrationISRCTN Identifier: ISRCTN92187251.

18 keywords...

hide…